SALT LAKE CITY, May 14, 2018 (GLOBE NEWSWIRE) — PolarityTE™, Inc. (NASDAQ:COOL) announced the acquisition of a preclinical biomedical research facility in order to accelerate research and development of PolarityTE pipeline products. The facility is an already fully-functional, operational and profitable contract research organization (CRO) which is regulated and compliant under both Good Laboratory Practices (GLP) and United States Department of Agriculture (USDA) standards.